Mogrify announced the initial close of its Series A funding, raising $16 million in this round, bringing the total investment to over $20 million to date.
The UK startup says the funding will support internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest. Led by CEO Darrin Disley, Mogrify launched in February 2019, driven by its proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
With the new funding, Mogrify says it will also increase headcount to 60 scientific, operational and commercial staff located at its state-of-the-art facility in Cambridge Science Park.
Read the press release
